OncoMatch/Clinical Trials/NCT07755826
Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan
Is NCT07755826 recruiting? Yes, currently enrolling (Sep 2026). Studying Repotrectinib for ntrk fusion-positive solid tumors.
Treatment: Repotrectinib — This study will collect safety information during routine medical care for children and adolescents in Japan who have been diagnosed with NTRK fusion-positive advanced or recurrent solid tumors who start treatment with repotrectinib. The study will describe how often side effects occur during treatment, with special attention to central nervous system disorders, interstitial lung disease, and fractures.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Tumor Agnostic
Biomarker criteria
Required: NTRK1 fusion
Required: NTRK2 fusion
Required: NTRK3 fusion
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07755826 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require NTRK1?
Yes, NTRK1 fusion is a required biomarker for enrollment.
Does this trial require NTRK2?
Yes, NTRK2 fusion is a required biomarker for enrollment.
Does this trial require NTRK3?
Yes, NTRK3 fusion is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 17 years or younger and at least 4 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages